INDGN Q2 FY27 Results & Earnings Analysis
Sentiment: Good (Confidence: high)
Earnings Summary
Indegene delivered strong Q2 FY27 results with revenue of INR11,223M (US$117.5M), up 39.5% YoY and 5.6% QoQ in INR terms, marking 5 consecutive quarters of >5% QoQ growth. EBITDA was INR1,873M at 16.7% margin (up 32% YoY) despite ~150 bps wage hike impact and lower interest income. PAT was INR1,123M (10% of revenue, up 10% YoY). Client base expanded to 107 active clients with 59 >$1M and 13 >$10M. Nine deal wins with ~$1M ACV including 3 large deals. BioPharm integration delivering with ~$1.5M cost synergies and >15% revenue growth trajectory. Management expects FY27 organic growth better than FY26, H2 stronger than H1, and EBITDA margins back to 19%+ by Q4 with margin growth outpacing revenue growth. Key risks include Tectonic ramp-up delays and change management challenges at largest client, offset by strong industry tailwinds from record pharma funding, approvals, and pipeline expansion.
Management Tone
- Prepared Remarks: Good — Prepared remarks highlighted strong industry tailwinds, record deal wins, BioPharm integration success, and confident outlook for H2 margin expansion and organic growth. Management emphasized inflection point in business model.
- Q&A Session: Neutral — Analysts probed on Tectonic ramp-up delays, margin trajectory, and client concentration movements. Management responses were mostly direct but acknowledged slower-than-expected ramp at largest client and change management challenges. Some questions on outcome-based revenue caps remained partially an
Revenue Growth Drivers
- Industry capital return and record approvals driving demand for commercialization services
- New deal wins and client expansion (9 deals, 107 active clients)
- BioPharm acquisition revenue contribution and integration synergies
Growth vs Margin Focus
Management explicitly targets both organic growth better than FY26 and quarterly EBITDA margins back to 19%+ by Q4. Confidence in achieving both from: wage cycle fully in base, outcome-linked omnichannel contract progressing, deal wins with healthy pipeline, and go-to-market investments beginning to
About Indegene Limited
Indegene Limited (INDGN) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.